Molecular approach to Turkish pediatric stroke patients

Turkish Journal of Haematology

Volumn 19, Issue 2, 2002, Pages 245-253

  Akar, Nejat ^a  

^a NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; BLOOD CLOTTING FACTOR 5; CELL PROTEIN; GLUTAMIC ACID; HOMOCYSTEINE; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; VERY LATE ACTIVATION ANTIGEN 2;

ALLELE; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; BLOOD CLOTTING; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CHILD; CHILDHOOD DISEASE; CLINICAL TRIAL; DATA BASE; DISEASE CARRIER; EXON; GENE; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; HAPLOTYPE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HYPERHOMOCYSTEINEMIA; INFORMATION PROCESSING; META ANALYSIS; MOLECULAR GENETICS; NEURAL TUBE DEFECT; PATHOGENESIS; PROMOTER REGION; REVIEW; RISK FACTOR; STROKE; THROMBOCYTE; THROMBOPHILIA; TURKEY (REPUBLIC);

EID: 0036399225     PISSN: 13007777     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (85)

1. Andrew M, Monaghe PT, Brooker L. Thromboembolic complications during infancy and childhood. BC Decker Inf, London, 2000.
2. Gürgey A, Aslan D. Outcome of noncatheter-related thrombosis in children: Influence of underlying or co-existence factors. J Ped Hemat/Onc 2001;23:159-64.
3. Turkis Pediatric Hematology Society. Pediatric thrombosis cases in Turkey. Ankara, 2001.
4. Butler IJ. Cerebrovascular disorders of childhood. J Child Neurol 1993;8:197-200.
5. Broderick J, Talbot T, Prenger E, et al. Stroke in children within a major metropolitan area: The surprising importance of intracerebral hemorrhage. J Child Neurol 1993;8:250-5.
6. Riela AR, Roach ES. Etiology of stroke in children. J Child Neurol 1993;8:201-20.
7. de Veber G, Mac Gregor D, Curtis R, Stephens D. Neurological outcome in survivors of childhood arterial ischemic stroke and sinovenous thrombosis. J Child Neurol 1999.
8. Nowak-Göttl U, Kosch A, Schlegel N. Thromboembolism in Newborns, infants and children. Thromb Haemost 2001;86:464-74.
9. Dahlback B, Carlsson M, Svennsson PJ. Familial thrombophilia due to a previously unrecognised mechanism characterized by poor anticoagulant response to activated protein C. Proc Natl Acad Sci USA 1993;90:1004-8.
10. Bertina RM, Koeleman BD, Koster T, Rosendal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
11. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-703.
12. de Veber G, Monagle P, Chan A. Prothrombotic disorders in infants and children with cerebral thromboembolism. Arch Neurol 1998;55:1539-43.
13. Bonduel M, Sciuccati G, Hepner M. Prethrombotic disorders in children with arterial ischemic stroke and sinovenous thrombosis. Arch Neurol 1999;56:967-71.
14. Vielhaber H, Ehrenforth S, Koch HG, Scharrer I, van der Werf, Nowak-Göttl U. Cerebral venous sinus thrombosis in infancy and childhood: Study of genetic and acquired risk factors of thrombophilia. Eur J Pediatr 1998;157:555-60.
15. Bertina RM, Koeleman RPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, van der Velden PA, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-7.
16. Akar N, Akar E, Dalgin G, Sözüöz A, Ömürlü K, Cin Ş. Frequency of factor V 1691 (G-A) mutation in Turkish population. Thromb Haemost 1997;78:1527-8.
17. Gül A, Özbek U, Öztürk C, Inanç M, Koniçe M, Özçelik T. Coagulation factor V gene mutation increases the risk of venous thrombosis in Behçet's disease. Br J Rheumatology 1996;35:1178-80.
18. Gürgey A, Mesci L. The prevalence of factor V Leiden (1691 G-- > A) mutation in Turkey. Turk J Pediatr 1997;39:313-5.
19. Akar N. Unpublished data.
20. Ganesan V, Kelsey H, Cookson J, Osbron A, Kirkham FJ. Activated protein C resistance in childhood stroke. Lancet 1996;347:260.
21. Nowak-Göttl U, Strater R, Dübbers A, et al. Ischemic stroke in infancy and childhood: Role of the Arg 506 to Gln mutation in the factor V gene. Blood Coagul Fibrinolysis 1996;7:684-8.
22. Simioni P, de Ronde H, Prandoni P, Saladini M, Bertina RM, Girolami A. Ischemic stroke in young patients with activated protein C resistance. A report of three cases belonging to three different kindreds. Stroke 1995;26:885-90.
23. Mc Coll MD, Chalmers EA, Thomas A, Sproul A, Healey C, Rafferty I, Mc Williams R, Eunson P. Factor F Leiden, prothrombin 20210 G-A and the MTHFR C677T mutations in childhood stroke. Thromb Haemost 1999;81:690-4.
24. Nowak-Göttl U, Strater R, Heinecke A, Junker R, Koch H, Schuierer G, von Eckardstein A. Lipoprotein (a) and genetic polymorphisms of clotting factor V, prothrombin and methylenetetrahydrofolate reductase are risk factors of spontaneous ischemic stroke in childhood. Blood 1999;94:3678-82.
25. Akar N, Akar E, Deda G, et al. Factor V 1691 G-A, prothrombin 20210 G-A and methylenetetrahydrofolate reductase 677 C-T variants in Turkish children with cerebral infant. J Child Neurol 1999;14: 749-51.
26. Kenet G, Sadetzki S, Murat H, Martinowitz U, Rosenberg N, Gitel S, Rechavi G, Inbal A. Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke 2000;31:1283-8.
27. Akar N, Akar E, Deda G, Sipahi T, Ezer Ü. Coexistence of two prothrombotic mutations, factor V 1691 G-A and prothrombin gene 202110 G-A and the risk of cerebral infarct in pediatric patients. Pediatric Hematology Oncology 1999;16:565-6.
28. Zens W, Bodo Z, Plotho J, Streif W, Male C, Bernert G, Rauter L, Ebetsberger G, Kaltenbrunner K, Kurnik P, Lischka A, Paky F, Ploier R, Höfler G, Mannhalter C, Muntean W. Factor V Leiden and prothrombin gene G20210 A variant in children with stroke. Thromb Haemost 1998;80:763.
29. Strater R, Vielhaber H, Kassenböhmer R, von Kries R, Göbel U, Nowak-Göttl U. Genetic risk factors of thrombophilia in ischaemic childhood stroke of cardiac origin. A prospective ESPED survey. Eur J Pediatr 1999;158(Suppl):122-5.
30. Olcay L, Gürgey A, Topaloǧlu H, Altay S, Parlak H, Firat M. Cerebral infarct associated with hemophilia A. Am J Hematol 1997;56:189-90.
31. Lunghi B, Iacoviello L, Gemmati D, di Iasio MG, Castoldi E, Pinotti M, Castaman G, Redaelli R, Mariani G, Marchetti G, Bernardi F. Detection of new ew polymorphic markers in the factor V gene: Association with factor V levels in plasma. Thromb Haemost 1996;75:45-8.
32. Bernardi F, Faioni EM, Castoldi E, Lunghi B, Castaman G, Sacchi E, Manucci PM. A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype. Blood 1997;90:1552-7.
33. Folsom AR, Cushman M, Tsai MY, Aleksic N, Heckbert SR, Boland LL, Tsai AW, Yanez ND, Rosamond WD. Prospective study of venous thromboembolism in relation to factor V Leiden and related factors: The longitudinal investigation of thromboembolism etiology (LITE). Thromb Haemost 2001;86(Suppl):325.
34. Castoldi E, Rosing J, Girelli D, Hoekma L, Lunghi B, Mingozzi F, Ferraresi P, Friso F, Corrocher R, Tans G, Bernardi F. Mutations in the R2 FV gene affect the ratio between the two isoforms in plasma. Thromb Haemost 2000;83:362-5.
35. Alhenc-Gelas M, Nicaud V, Gandrille S, van Dreden P, Amiral J, Aubry ML, Fiessinger JN, Emmerich J, Aiach M. The factor V gene A4070G mutation and the risk of venous thrombosis. Thromb Haemost 1999;81:193-7.
36. Lluddington R, Jackson A, Pannerselvam S, Brown K, Baglin T. The factor V R2 allele: Risk of venous thromboembolism, factor V levels and resistance to activated protein C. Thromb Haemost 2000;83:204-8.
37. Margaglione M, Bossone A, Coalizzo D, D'Andrea G, Brancaccio V, Ciampa A, Grandole E, Di Minno G. FV HR2 haplotype as additional inherited risk factor for deep vein thrombosis in individuals with a high risk profile. Thromb Haemost 2002;87:32-6.
38. De Visser MCH, Guash JF, Kamphuisen PW, Vos HL, Rosendaal FR, Bertine RM. The HR2 haplotype of factor V: Effects on factor V levels, normalised activated protein C sensitivity ratios and the risk of venous thrombosis. Thromb Haemost 2000;83:577-82.
39. Benson JM, Ellingsen D, El-Jamil M, Jenkins M, Miller CH, Dilley A, Evatt BL, Hooper WC. Factor V Leiden and factor V R2 allele: High-throughput analysis and association with venous thromboembolism. Thromb Haemost 2001;86:1182-92.
40. Akar N, Akar E, Yilmaz E. Factor V (his 12999 Arg) in Turkish patients with venous thromboembolism. Am J Hematol 2000;63:102-3.
41. Faioni EM, Franchi F, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Finazzi G, Mannucci PM. Coinheritance of the HR2 haplotype in the factor V gene confers an increased risk of venous thromboembolism to carriers of factor V R506Q. Blood 1999;94:3062-4.
42. Akar N, Akar E, Yilmaz E, Cin S. Coexistence of factor V 1691 G-A and factor V 4070 A-G mutation in Turkish thromboembolic patients. Am J Hematol 2000;65:88.
43. Akar N, Akar E, Yilmaz E, Sözüöz A. Frequency of FV 1299 His-Arg (A4070G) in Turkish Cypriots. Turk J Haematol 2001;18:243-4.
44. Sipahi T, Huner C, Yildiz YT, Akar N. Inherited protein-C deficiency, FV G 1691A and FV A4070G mutations in a child with internal cerebral venous thrombosis. Pediatric Radiology 2000;30:420-3.
45. Akar N, Kemahli S, Deda G, Akar E, Yilmaz E, Uysal Z, Cin Ş. Multiple cerebral emboli in a homozygous β-thalassemia patient due to factor V 1299 (His-Arg) 4070 A-G mutation. Turk J Haematology 2000;17:133-6.
46. Akar N, Yilmaz E, Akar E, Deda G, Sipahi T. FV1299 in young Turkish patients with cerebral infarct. Haemostasis 2000;30:118-22.
47. Akar N, Misirlioǧlu M, Akar E, Avcu F, Yalçin A, Sözüöz A. Prothrombin gene 20210 G-A mutation in the Turkish population. Am J Hematol 1998;58:249.
48. Gürgey A, Hicsonmez G, Parlak H, Balta G, Celiker A. Prothrombin gene 20210 G-A mutation in Turkish patients with thrombosis. Am J Hematol 1998;59:179-80.
49. Sipahi T, Duru F, Ciftci E, Sahin F, Akar N. Cerebral infarct associated with prothrombin gene G20210A variant in a Turkish child with cystic fibrosis: An unusual coexistence. European Journal of Haematology 1999;62:281-3.
50. Berberoǧlu M, Öcal G, Akar N, Adiyaman P, Çetinkaya F, Deda G. Hereditary isolated glucocorticoid deficiency with prothrombin 20210 G/A heterozygous gene mutation. Horm Res 1998;50(Suppl 3):134.
51. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, Graham I. Hyperhomocysteinemia: An independent risk factor for vascular disease. New Eng J Med 1991;324:1149-55.
52. den Heijer M, Koster T, Blom HJ, Bos GMJ, Briet E, Reitsma PH, van den Broucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep vein thrombosis. New Eng J Med 1996;334:759-62.
53. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Mathews RG, Boers GHJ, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R. A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995;10:111-3.
54. vander Put NMJ, Gabreels F, Stevens EMB, Smeitink JAM, Trijbels FJM, Eskes TKAB, van den Heuvel L, Blom HJ. A second common mutation in the methylenetetrahydrofolate reductase gene: An additional risk factor for neural-tube defects. Am J Hum Genet 1998;62:1051.
55. Akar N, Akar E, Özel D, Deda G, Sipahi T. Common mutations at the homocysteine metabolism pathway and pediatric stroke. Thrombosis Research 2001;102:115-20.
56. Wiman B, Hamsten A. Impaired fibrinolysis and risk of thromboembolism. Prog Cardiovasc Dis 1991;34:179-92.
57. Stegnar M, Uhrin P, Peternel P, et al. The 4G/5G sequence polymorphism in the promoter of plasminogen activator inhibitor-1 (PAI-1) gene: Relationship to plasma PAI-1 level in venous thromboembolism. Thromb Haemost 1998;79:975-9.
58. Junker R, Nabavi DG, Wolff E, et al. Plasminogen activator inhibitor-1 4G/5G genotype is associated with cerebral sinus thrombosis in factor V Leiden carriers. Thromb Haemost 1998;80:706-7.
59. Akar N, Yilmaz E, Akar E, et al. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV 1691 G-A. Thromb Research 2000;97:227-30.
60. Roest M, van der Schouw YT, Banga JD, et al. Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation 2000;101:67-70.
61. Akar N, Akar E, Yilmaz E, Deda G. Plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish children with cerebral infarct and effect on factor V 1691 A mutation. Journal of Child Neurology 2001;16:294
62. Novak-Göttl U, Strater R, Kosch A, von Eckardstein A, Schobess R, Luigs P, Nabel P, Vielhaber H, Kurnik K, Junker R. The plasminogen activator inhibitor (PAI-1) promoter 4G/5G genotype is not associated with ischemic stroke in a population of German children. Eur J Haemost 2001;66:57-62.
63. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Eng J Med 1993;329:2002-12.
64. Marsden PA. Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem 1993;268:17478-88.
65. Wang XL, Mahaney MC, Sim AS, Wang J, Blangero J, Almasy L, Badenhop RB, Wilcken DE. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arteriscler Thromb Vasc Biol 1997;17:3147-53.
66. Akar N, Akar E, Deda G. No association with eNOS 296 and cerebral stroke. Neurology 2000;55:456-8.
67. Santoso SA, Zutter MM. The α2β1 integrin: A collagen receptor on platelets and other cells. Thromb Haemost 1995;74:813-21.
68. Nieuwenhuis HK, Akkerman JWN, Houdijk WPM. Sixma JJ. Human blood platelets showing no response to collagen fail to express surface glycoprotein Ia. Nature 1985;318:470-2.
69. Kehrel B, Balleisen L, Kokott R, et al. Deficiency of intact thrombospondin and membrane glycoprotein Ia in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood 1988;71:1074-8.
70. Handa M, Watanabe K, Kawai Y, et al. Platelet unresponsiveness to collagen: Involvement of glycoprotein Ia-IIa (α2β1 integrin) deficiency associated with a myeloproliferative disorder. Thromb Haemost 1995;73:521.
71. Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin α2β1 density is associated with two silent polymorphisms in the α2 gene coding sequence. Blood 1997;89:1939-43.
72. Kunicki TJ, Orchekowski R, Annis D, Honda Y. Variability of integrin α2β1 activity on human platelets. Blood 1993;82:2693-703.
73. Kritzik M, Savage B, Nugent DJ, et al. Nucleotide polymorphisms in the α2 gene define multiple alleles that are associated with differences in platelet α2β1 density. Blood 1998;92:2382-8.
74. 873 of the platelet collagen receptor integrin α2β1 might be a genetic risk factor for the development of stroke in younger patients. Blood 1999;93:3583-6.
75. Akar N, Duman T, Akar E, Deda G, Sipahi T. The alpha 2 gene alleles of the platelet collagen receptor integrin alpha 2 beta 1 in Turkish children with cerebral infarct. Thrombosis Research 2001;102:121-3.
76. Esmon CT. The endothelial cell protein C receptor. Thromb Haemost 2000;83:639-43.
77. Simmonds RE, Lane DA. Structural and functional implications of the intron/exon organisation of the human endothelial cell protein C/activated protein C receptor (EPCR) gene: Comparison with the structure of CD1/major histocompatibility complex α1 and α2 domains. Blood 1999;94:632-41.
78. Merati G, Biguzzi E, Oganesyan N, Fetiveau R, Qu DF, Bucciarelli P, Stearns DJ, Mannucci PM, Esmon CT, Faioni EM. A 23 bp insertion in the endothelial protein C receptor gene in patients with myocardial infarction and deep vein thrombosis. Thromb Haemost 1999;507.
79. Akar N, Gökdemir R, Akar E, Özel D. Endothelial cell protein C/activated protein C receptor gene exon III, 23 BP insertion mutation in Turkish pediatric thrombotic patients. The Journal Thrombosis and Haemostasis, 2001(Suppl).
80. Balta G, Gurgey A, Kudayarov DK, Tunc B, Altay C. Evidence for the existence of the PAF acetylhydrolase mutation (Val279Phe) in non-Japanese populations: A preliminary study in Turkey, Azerbaijan, and Kirgizstan. Thromb Res 2001;15;101:231-4.
81. Wilson A, Symons I, Mc Dowell T, Mc Devitt H. Effects of a polymorphism in the human tumour necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci 1997;94:3195-9.
82. Brown K, Luddington R, Baglin T. A common polymorphism in the tumour necrosis factor-alpha gene associated with high TNF levels is not a risk factor for venous thromboembolism. Br J Haematol 1998;101:480-2.
83. Bertolaccini ML, Atsumi T, Lanchbury JS, Caliz AR, Katsumata K, Vaughan RW, Kondeatis E, Khamashta MA, Koike T, Hughes GRV. Plasma tumor necrosis factor α levels and the -238 A promoter polymorphism in patients with antiphospholipid syndrome. Thromb Haemost 2001;85:198-203.
84. Carroll JE, McKie V, Kutlar A. Are sickle cell disease patients with stroke genetically predisposed to the event by inheriting a tendency to high tumor necrosis factor levels? Am J Hematol 1998;58:250.
85. Akar N, Hasipen M, Akar E. TNF-alpha-308 G-A in Turkish pediatric thrombosis patients. Turk J Hemat 2002.